Chemical & Pharmaceuticals

Sectors

RPS Engineering Services provides its clients with the design, engineering and technical support services they need to succeed in the global pharmaceutical, biotechnology and medical device marketplace.

RPS understands the overall goals of this sector to continuously improve economic, social and environmental performance and has established an excellent reputation with our clients for the provision of specialist consultancy services.

We combine understanding of sector specific regulatory and operating environments with knowledge and experience of cross-sector good practice. Our experience covers a range of project types from masterplanning of facilities to start-up, including design, project management, procurement, validation, commissioning and technical support.

RPS provides support for the management of safety and health, including the Control of Major Accident Hazards (COMAH).

Working alongside the client, we can support all phases of an installation from conceptual design through to decommissioning, helping ensure that industry stays safe, profitable and competitive. RPS personnel are capable of working at all levels within an organisation thus ensuring stakeholder participation in projects undertaken, which benefits the project and the overall safety culture.

Our services include:

Hazard Studies (e.g. Hazard Identification & HAZOP)

Risk Management

Fire and ATEX / DSEAR Risk Assessment

Planning support

EIA / IPPC support

Occupational Health Services

Occupational Hygiene Services

Stack Emissions Monitoring

Air Dispersion Modelling

Groundwater Monitoring

Nuisance Dust Assessments

Odour Management

IPPC Applications and Improvement Conditions

Fire and Explosion Modelling

GHS Implementation

COMAH Support


Case Studies

Abbott Pharmaceuticals

Chemical Risk Assessment – Abbott Pharmaceuticals, Ireland Chemical Risk Assessment – Abbott Pharmaceuticals, Ireland

Abbott Pharmaceuticals

RPS was appointed by Abbott Pharmaceuticals to conduct a chemical risk assessment.

RPS were involved in development of chemical risk inventory including MSDS control for all applicable materials on site and the development of procedures for the transport and movement of chemicals around the site, storage and labelling of chemicals and reviewing the arrangements for storage, labelling and control of gas cylinders on site.

Allergan Pharmaceuticals

Allergan Pharmaceuticals, Ireland Allergan Pharmaceuticals, Ireland

Allergan Pharmaceuticals Ireland

RPS has been engaged in a programme of continuous capital expenditure over a number of years to develop all aspects of the Allergan facility.

Allergan Inc. is a premier, global specialty pharmaceutical company that develops and commercialises innovative products for the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other speciality markets.

Allergan Pharmaceuticals Ireland, a subsidiary of Allergan Inc., is based in Westport, Co. Mayo. Established in 1977, the current facility has grown to over 500,000 sq/ft on a 30 acre campus and includes state-of-the-art chemistry, microbiology and stability laboratories. Manufacturing operations include automated pharmaceutical and biologic filling and packaging lines.

Currently, RPS is engaged on a substantial manufacturing expansion, to construct a new Vial Fill Finish Facility with project costs for this phase in excess of €120m. RPS design, engineer and specify the mechanical, HVAC, process equipment and clean utilities for all aspects of the site. We also assisted Allergan with environmental aspects on the site.

Spent Catalyst Waste Assessment

Spent Catalyst Waste Assessment, Ireland Spent Catalyst Waste Assessment, Ireland

Novartis

RPS were appointed by Novartis Ringaskiddy Limited to carry out an assessment of spent catalyst waste arising from the production of a particular pharmaceutical product, to determine if the waste could be classified as hazardous or non-hazardous.

The spent catalyst waste stream was classified using the EPA’s “Paper Tool of the Procedure for the Identification of the Hazardous Components of Waste”, Volume I (Clean Technology Centre, August 2004).

RPS were responsible for the interpretation of the laboratory results, the classification of the waste using the EPA’s paper tool and preparation of a final report outlining the sampling procedure, laboratory analysis and classification of the spent catalyst waste for submission to the EPA. The final report has been submitted to the EPA for comment. Similar work for the classification of bottom ash and slag from the solid waste incinerator is ongoing.